<DOC>
	<DOCNO>NCT01858948</DOCNO>
	<brief_summary>The investigator test hypothesis adverse effect second-generation antipsychotic exposure beneficial effect long-chain omega-3 ( LCn-3 ) fatty acid mediate oppose effect enzyme implicate metabolic syndrome obesity .</brief_summary>
	<brief_title>SGA-induced Metabolic Syndrome Bipolar Youth</brief_title>
	<detailed_description>This two-phase study design : Phase I : prospectively investigate relationship baseline LCn-3 fatty acid status treatment-emergent adverse cardiometabolic event weight gain response acute ( 6-week ) open-label quetiapine first-episode adolescent manic patient ( age 12-17 year ) . SGA-na√Øve acutely manic patient treat open-label quetiapine 6-weeks . Patients start 100 mg BID quetiapine , dose adjust base tolerability response . The quetiapine target dose 400-600 mg , subject range 200-500 mg . Phase II : Patients Phase I randomize double-blind adjunctive treatment LCn-3 fatty acid placebo additional 24 week investigate protective effect progression resolution adverse cardiometabolic event weight gain quetiapine maintenance therapy . They 6 visit 24-week period .</detailed_description>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>DSMIVTR criterion bipolar disorder , type I , manic mixed episode Baseline YMRS score &gt; 20 Ages 1017 year Tanner scale stage IIIV No prior exposure SGA medication Fluent English Provision write informed consent legal guardian write assent subject Manic depressive symptom result entirely acute medical illness acute intoxication withdrawal drug alcohol determine medical evaluation rapid symptom resolution If female child bear potential , agree use one follow method birth control : complete abstinence sexual intercourse , barrier ( diaphragm condom ) , oral/injectable contraceptive . For Phase II , additional Inclusion criterion Receiving stable therapeutic dose quetiapine minimum 1 week ( i.e. , patient achieve remission ( YMRS total score 7 Phase I ) Not require concomitant use antidepressant moodstabilizer medication ( see Section C.4.c . Concomitant Medications ) . IQ &lt; 70 , determine The Wechsler Abbreviated Scale Intelligence Positive pregnancy test ( avoid teratogenesis ) A history major cardiovascular neurological illness Any lifetime DSMIVTR substance use disorder ( nicotine dependence permit ) A lifetime DSMIVTR diagnosis pervasive developmental disorder Any history hematological disorder firstdegree relative exclude ( since omega3 fatty acid may associate antithrombotic effect ) . Similarly , concomitant use medication anticoagulant effect ( e.g . aspirin ) prohibit Allergy fish/seafood ; 8 ) Currently take omega3 fatty acid supplement</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Bipolar disorder</keyword>
	<keyword>Second-generation antipsychotic</keyword>
	<keyword>Obesity</keyword>
	<keyword>Cardiometabolic risk</keyword>
</DOC>